In this trial, infants who had received enhanced PN did so without increased metabolic complications such as hyperglycemia, hypertriglyceridemia, hyperbilirubinemia, or increased days of insulin use when compared to the control group. This evidence concerns the gene INS and Hyperbilirubinemia.